XTORO 0.3 %
FINAFLOXACIN : 0.3 % · DIN 02452928 · MERLION PHARMACEUTICALS GMBH
Health Canada status: APPROVED
What is XTORO?
XTORO 0.3 % contains FINAFLOXACIN : 0.3 %. It is listed in the Health Canada Drug Product Database under DIN 02452928, held by MERLION PHARMACEUTICALS GMBH, supplied as SUSPENSION for OTIC administration. Health Canada currently lists it as approved, status dated 11-Mar-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02452928 |
|---|---|
| Brand name | XTORO |
| Generic / active ingredient | FINAFLOXACIN : 0.3 % |
| Manufacturer | MERLION PHARMACEUTICALS GMBH |
| Strength | 0.3 % |
| Dosage form | SUSPENSION |
| Route of administration | OTIC |
| Schedule | Prescription |
| ATC code | S02AA ANTIINFECTIVES |
| AHFS class | 52:04.04 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 11-Mar-2019 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.